Cempra is a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases. The Company's lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, for the treatment of community-acquired bacterial pneumonia, or CABP, one of the most serious infections of the respiratory tract in adults and children, as well as for ophthalmic infections and other indications.

Company Growth (employees)
Type
Public
HQ
Chapel Hill, US
Founded
2006
Size (employees)
45 (est)
Website
cempra.com
Cempra was founded in 2006 and is headquartered in Chapel Hill, US

Key People at Cempra

Prabhavathi Fernandes

Prabhavathi Fernandes

President & CEO
Mark Hahn

Mark Hahn

EVP & CFO
David Moore

David Moore

EVP & CCO

Cempra Office Locations

Cempra has an office in Chapel Hill
Chapel Hill, US (HQ)
360 6320 Quadrangle Dr

Cempra Data and Metrics

Cempra Financial Metrics

Cempra's revenue was reported to be $4.9 m in Q1, 2017
USD

Revenue (Q1, 2017)

4.9 m

Net income (Q1, 2017)

(22.9 m)

EBIT (Q1, 2017)

(22.9 m)

Market capitalization (17-Aug-2017)

157.5 m

Cash (31-Mar-2017)

202.8 m
Cempra's current market capitalization is $157.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

7.8 m15.2 m27.3 m18 m

Revenue growth, %

95%79%(34%)

R&D expense

41.3 m62.5 m93.4 m81.7 m

General and administrative expense

9.4 m12.1 m22.9 m53.5 m

Operating expense total

50.7 m74.6 m116.2 m135.2 m

EBIT

(42.9 m)(59.4 m)(88.9 m)(117.2 m)

EBIT margin, %

(549%)(390%)(326%)(651%)

Interest expense

(2.1 m)(2.4 m)(2.2 m)(1.2 m)

Interest income

17.7 k134.4 k8.8 k475 k

Net Income

(45 m)(61.6 m)(91.1 m)(118 m)
USDQ2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

1.9 m7.8 m5.1 m2.5 m2.7 m3.4 m4 m4.9 m

R&D expense

15.2 m15.7 m23.7 m23.5 m23.5 m16 m21.1 m15.4 m

General and administrative expense

2.6 m2.9 m5.7 m5.8 m8.3 m12 m15 m8.8 m

Operating expense total

17.8 m18.5 m29.4 m29.4 m31.9 m28 m36.1 m24.2 m

EBIT

(15.9 m)(10.7 m)(24.4 m)(26.9 m)(29.2 m)(24.6 m)(32.1 m)(22.9 m)

EBIT margin, %

(839%)(138%)(482%)(1077%)(1089%)(719%)(809%)(469%)

Interest expense

(559.7 k)(615.9 k)(617.4 k)(678.9 k)(330 k)(323 k)(295 k)(243 k)

Interest income

88.1 k5151.8 k38298 k104 k128 k211 k

Net Income

(33.4 m)(44.8 m)(42.4 m)(70 m)(29.4 m)(54.2 m)(86.5 m)(22.9 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

96.5 m99.1 m153.8 m231.6 m

Accounts Receivable

199.9 m

Inventories

7.5 m13.4 m

Current Assets

98.5 m104.9 m162 m238.3 m

Total Assets

99 m105.3 m162.1 m238.5 m

Accounts Payable

6.3 m11.9 m9.6 m15.7 m

Total Debt

14.7 m18.5 m19.7 m15.3 m

Current Liabilities

10.9 m18.1 m17.9 m29.5 m

Total Liabilities

55.2 m

Additional Paid-in Capital

236.2 m288.9 m436.6 m620.3 m

Retained Earnings

(166.3 m)(227.9 m)(319 m)(437 m)

Total Equity

117.7 m183.3 m

Debt to Equity Ratio

0.2 x0.1 x

Debt to Assets Ratio

0.1 x0.2 x0.1 x0.1 x

Financial Leverage

1.4 x1.3 x
USDQ2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

68.6 m74.2 m202.4 m182 m223.6 m250.7 m248.9 m202.8 m

Current Assets

72.9 m81.5 m207.9 m186.5 m228.7 m256.1 m254.2 m210.3 m

Total Assets

73.5 m82 m208.1 m186.7 m228.9 m256.4 m254.4 m210.5 m

Accounts Payable

9.4 m10.8 m13.8 m14.9 m11.2 m14.5 m12.5 m11.8 m

Current Liabilities

11.1 m15.2 m21.8 m21.1 m19.3 m24.7 m25 m23.7 m

Additional Paid-in Capital

238.7 m249.9 m432.8 m435.1 m533 m581.6 m613.3 m622.6 m

Retained Earnings

(199.7 m)(211 m)(270.3 m)(297.9 m)(348.4 m)(373.2 m)(405.5 m)(459.9 m)

Total Equity

162.6 m137.3 m184.6 m208.4 m207.9 m162.8 m

Financial Leverage

1.3 x1.4 x1.2 x1.2 x1.2 x1.3 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(45 m)(61.6 m)(91.1 m)(118 m)

Depreciation and Amortization

39.6 k76.3 k69.2 k51 k

Inventories

(617 k)(1.2 m)(153.6 m)5.2 m

Accounts Payable

4.1 m5.6 m(2.3 m)6 m

Cash From Operating Activities

(32.4 m)(49.1 m)(87.8 m)(87.1 m)

Cash From Investing Activities

(134.1 k)(51.7 k)(45.8 k)(9 k)

Long-term Borrowings

(238.3 k)(19 m)(4.4 m)

Cash From Financing Activities

59 m51.8 m142.5 m164.9 m

Interest Paid

1.2 m1.6 m1.5 m1.2 m
USDQ2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(33.4 m)(44.8 m)(42.4 m)(70 m)(29.4 m)(54.2 m)(86.5 m)(22.9 m)

Depreciation and Amortization

29.8 k44.9 k39.5 k54.4 k14.9 k30 k40 k9 k

Accounts Payable

3.1 m4.5 m1.9 m3 m1.6 m4.9 m2.9 m(3.9 m)

Cash From Operating Activities

(30.8 m)(35.9 m)(37.3 m)(59.5 m)(24.2 m)(41.9 m)(71.3 m)(27.2 m)

Cash From Investing Activities

(36.7 k)(36.7 k)(45.8 k)(45.8 k)(46 k)(9 k)(9 k)

Cash From Financing Activities

3 m13.6 m140.6 m142.5 m94 m138.8 m166.4 m(1.6 m)

Interest Paid

724.2 k1.1 m869 k1.2 m322 k625 k916 k241 k
USDY, 2017

Revenue/Employee

108.3 k

Financial Leverage

1.3 x

Cempra Market Value History

Traffic Overview of Cempra

Cempra Online and Social Media Presence

Cempra Company Life and Culture

You may also be interested in